DAFTAR PUSTAKA

1.   Jones DS. History in a crisis—lessons for Covid-19. New England journal of medicine. 2020;382(18):1681–3.
2.   Cascella M, Rajnik M, Aleem A, Dulebohn SC, di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). Statpearls [internet]. 2022;
3.   Organization WH. COVID-19 weekly epidemiological update, edition 94, 1 June 2022. 2022;
4.   Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England journal of medicine. 2020;
5.   Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497–506.
6.   Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 2020;395(10223):507–13.
7.   Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. New England journal of medicine. 2020;382(10):970–1.
8.   Ryu S, Chun BC, of Epidemiology KS. An interim review of the epidemiological characteristics of 2019 novel coronavirus. Epidemiol Health. 2020;42.
9.   Raychaudhuri S, Pujani M, Menia R, Verma N, Singh M, Chauhan V, et al. COVID-19 Associated Coagulopathy in an Indian scenario: A correlation with disease severity and survival status. Indian Journal of Hematology and Blood Transfusion. 2022;38(2):341–51.
10.   Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 Jun;135(23):2033–40.
11.   Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet. 2020;395(10229):1033–4.
12.   Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis. 2020;18(5):1094–9.
13.   Willyard C. Coronavirus blood-clot mystery intensifies. Nature. 2020;581(7808):250.
14.   Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. Journal of thrombosis and haemostasis. 2020;18(6):1324–9.
15.   Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis. 2020;18(4):844–7.

16. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497–506.

17. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–9.

18. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clinica chimica acta. 2020;506:145–8.

19. Katneni UK, Alexaki A, Hunt RC, Schiller T, DiCuccio M, Buehler PW, et al. Coagulopathy and thrombosis as a result of severe COVID-19 infection: a microvascular focus. Thromb Haemost. 2020;120(12):1668–79.

20. Han H, Yang L, Liu R, Liu F, Wu K lang, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clinical Chemistry and Laboratory Medicine (CCLM). 2020;58(7):1116–20.

21. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis. 2020;18(4):844–7.

22. Fogarty H, Townsend L, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Browne P, et al. COVID19 coagulopathy in Caucasian patients. Br J Haematol. 2020;189(6):1044–9.

23. Ramasamy R, Milne K, Bell D, Stoneham S, Chevassut T. Molecular mechanisms for thrombosis risk in Black people: a role in excess mortality from COVID-19. Br J Haematol. 2020;

24. Wang Z, Qiang W, Ke H. A handbook of 2019-nCoV pneumonia control and prevention. Hubei Science and Technologi Press China. 2020;

25. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses. 2015;1–23.

26. Jha NK, Jeyaraman M, Rachamalla M, Ojha S, Dua K, Chellappan DK, et al. Current understanding of novel coronavirus: molecular pathogenesis, diagnosis, and treatment approaches. Immuno. 2021;1(1).

27. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clinical immunology. 2020;215:108427.

28. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. American Journal of Physiology-Endocrinology and Metabolism. 2020;318(5):E736–41.

29. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis. 2020;18(9):2103–9.

30. Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflammation Research. 2020;69(12):1181–9.

31. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):1–8.

32. Gomez-Mesa JE, Galindo-Coral S, Montes MC, Martin AJM. Thrombosis and Coagulopathy in COVID-19. Curr Probl Cardiol. 2021;46(3):100742.

33. Shi Y, Wang G, Cai X peng, Deng J wen, Zheng L, Zhu H hong, et al. An overview of COVID-19. Journal of Zhejiang University-SCIENCE B. 2020;21(5):343–60.

34. Guan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708–20.

35. Organization WH. Therapeutics and COVID-19: living guideline, 31 March 2021. World Health Organization; 2021.

36. Indonesia PDP, Indonesia PDSK, Anestesiologi PD, Indonesia TI, Indonesia IDA. Pedoman Tatalaksana COVID-19 edisi 4. PDPI. 2021;4.

37. Mehrdad R, Zahra K, Mansouritorghabeh H. Hemostatic system (Fibrinogen level, D-Dimer, and FDP) in severe and Non-Severe patients With COVID-19: a systematic review and meta-Analysis. Clinical and Applied Thrombosis/Hemostasis. 2021;27:10760296211010972.

38. Nugroho J, Wardhana A, Mulia EP, Maghfirah I, Rachmi DA, A'yun MQ, et al. Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: A meta-analysis. Clin Hemorheol Microcirc. 2021;77(2):221–31.

39. Di Minno MND, Calcaterra I, Lupoli R, Storino A, Spedicato GA, Maniscalco M, et al. Hemostatic changes in patients with COVID-19: a meta-analysis with meta-regressions. J Clin Med. 2020;9(7):2244.

40. Zhang A, Leng Y, Zhang Y, Wu K, Ji Y, Lei S, et al. Meta-analysis of coagulation parameters associated with disease severity and poor prognosis of COVID-19. International Journal of Infectious Diseases. 2020;100:441–8.

41. Sui J, Noubouossie DF, Gandotra S, Cao L. Elevated plasma fibrinogen is associated with excessive inflammation and disease severity in COVID-19 patients. Front Cell Infect Microbiol. 2021;11:734005.

42. Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis. Eur J Med Res. 2020;25(1):1–10.

43. Zhan H, Chen H, Liu C, Cheng L, Yan S, Li H, et al. Diagnostic value of D-dimer in COVID-19: a meta-analysis and meta-regression. Clinical and Applied Thrombosis/Hemostasis. 2021;27:10760296211010976.

44. Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. Thromb Res. 2020;195:219–25.

45. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205–8.

46. Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med. 2020;201(11):1430–4.

47. Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, B. Pearson CA, et al. COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med. 2020;18:1–22.

48. Chiam T, Subedi K, Chen D, Best E, Bianco FB, Dobler G, et al. Hospital length of stay among COVID-19-positive patients. J Clin Transl Res. 2021;7(3):377.

49. Birhanu A, Merga BT, Ayana GM, Alemu A, Negash B, Dessie Y. Factors associated with prolonged length of hospital stay among COVID-19 cases admitted to the largest treatment center in Eastern Ethiopia. SAGE Open Med. 2022;10:20503121211070370.

50. Cotter AH, Yang SJT, Shafi H, Cotter TM, Palmer-Toy DE. Elevated von Willebrand factor antigen is an early predictor of mortality and prolonged length

of stay for coronavirus disease 2019 (COVID-19) inpatients. Arch Pathol Lab Med. 2022;146(1):34–7.

51. Chen FJ, Li FR, Zheng JZ, Zhou R, Liu HM, Wu KY, et al. Factors associated with duration of hospital stay and complications in patients with COVID-19. J Public Health Emerg. 2021;5(0):6.

52. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020;75(7):1742–52.

53. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA [Internet]. 2020 Mar 17;323(11):1061–9. Available from: https://doi.org/10.1001/jama.2020.1585

54. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7.

55. Wan S, Xiang YI, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92(7):797–806.

56. Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol. 2020;51(5):343–8.

57. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol [Internet]. 2020;52(6):1193–4. Available from: https://doi.org/10.1007/s11255-020-02451-9

58. Bae S, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021;107(5):373–80.

59. Zhang J jin, Dong X, Liu G hui, Gao Y dong. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol. 2023;64(1):90–107.